Armodafinil

One half of modafinil

Modafinil contains two mirror-image forms, R and S. Armodafinil is the isolated R-form. The R-form leaves the body more slowly than the S-form, which helps explain the different exposure profiles.^765,766

How long it stays in the body

A pooled analysis of 119 healthy participants found a half-life of about 15 hours and a peak concentration around two hours after a fasting dose. Food delayed the peak by two to four hours. With repeated daily dosing, steady state appeared within seven days.⁷⁶⁶

The mechanism

The exact wake-promoting mechanism remains partly understood. The label describes actions similar to modafinil, which binds the dopamine transporter and reduces dopamine reuptake.⁷⁶⁴

Sleep trials

Narcolepsy

A 12-week trial randomized 196 adults. Average time awake during the daytime test increased by 1.3 minutes with 150 mg and 2.6 minutes with 250 mg, while falling by 1.9 minutes with placebo. Clinician ratings improved in 69% and 73% of the active groups, compared with 33% with placebo.⁷⁶⁷

Sleep apnea and CPAP

Two 12-week trials randomized 395 and 263 adults who remained sleepy despite documented CPAP use. Average wake-test improvement over placebo was 3.4 to 3.9 minutes in the first trial and 3.6 minutes in the second. CPAP continued throughout treatment.⁷⁶⁴

Shift-work disorder

A 12-week trial enrolled 254 night-shift workers with diagnosed shift-work disorder. Average time before falling asleep in the night-time test rose from 2.3 to 5.3 minutes with armodafinil, compared with 2.4 to 2.8 minutes with placebo. Clinician ratings improved in 79% versus 59%.⁷⁶⁸

Persistent sleepiness

The label asks clinicians to reassess sleepiness during treatment, including its effect on driving and hazardous work. A person can remain sleepy even when the average trial result improves.⁷⁶⁴

Focus and longer use

The direct modafinil comparison

A 12-week Indian trial compared armodafinil 150 mg with modafinil 200 mg in 211 people with shift-work sleep disorder. Subjective sleepiness response rates were 72.12% and 74.29%, respectively, with no significant difference. The trial measured response in this population and was not designed to establish equivalence.⁷⁶⁹

Attention during sleep loss

In 135 healthy men undergoing acute sleep loss, armodafinil and lisdexamfetamine both improved sustained attention and time awake compared with placebo. The experiment tested a single exposure during sleep deprivation.⁷⁷⁰

Attention after a workday

A placebo-controlled study of 48 Naval air traffic control students found fewer attention lapses eight to eleven hours after one dose. Participants completed a standard workday before testing. The abstract leaves their baseline sleep duration unclear.⁷⁸⁹

Cognitive results vary by condition

A small multiple-sclerosis study found better delayed verbal recall but no improvement in several other cognitive measures. Trials in HIV-related fatigue and schizophrenia found no overall cognitive advantage. The strongest clinical evidence remains wakefulness in sleep disorders.^771,772,773

Bipolar depression

The adjunctive-treatment program had mixed results. A trial with 433 randomized adults met its primary depressive-symptom endpoint; trials with 492 and 399 adults did not. Each tested armodafinil alongside maintenance treatment for bipolar I disorder.^774,775,776

Cancer-related fatigue

A phase 3 glioma trial enrolled 328 adults, with 297 evaluable for the main endpoint. Meaningful fatigue improvement occurred in 28% of each armodafinil group and 30% of the placebo group.⁷⁷⁷

Side effects and interactions

Common side effects

Across pooled trials with 645 armodafinil and 445 placebo recipients, headache occurred in 17% versus 9%, nausea in 7% versus 3%, dizziness in 5% versus 2%, and insomnia in 5% versus 1%.⁷⁶⁴

Symptoms that need prompt attention

The label warns about serious rash, multiorgan hypersensitivity, swelling and severe allergic reactions. Fever or swollen lymph nodes may appear before a rash. Psychiatric reactions, including mania, hallucinations and suicidal thoughts, are also reported.⁷⁶⁴

Blood pressure and pulse

Short trials found average blood-pressure increases of 1.2 to 4.3 mmHg over placebo and pulse increases of 0.9 to 3.5 beats per minute. New or increased blood-pressure treatment was needed by 2.9% of armodafinil recipients and 1.8% of placebo recipients.⁷⁶⁴

Dependence and withdrawal

Armodafinil is a US Schedule IV controlled substance. The label describes abuse, physical dependence and withdrawal after abrupt stopping or a large dose reduction following chronic use. The reports do not provide a reliable frequency.^764,779

Other medicines and scans

Armodafinil can change exposure to contraceptives, cyclosporine, some seizure medicines and several other drugs. Australian product information updated in April 2026 also warns that it can interfere with dopamine-transporter imaging such as DaTSCAN. The imaging team needs an accurate medication list.^764,780,781

Pregnancy and regional evidence

France study

A 2026 French study compared 786 modafinil-exposed pregnancies with 3,144 matched unexposed pregnancies. Major malformations occurred in 4.2% versus 3.3%; the adjusted risk ratio was 1.32 (95% CI 0.81 to 2.15). This study assessed modafinil, and the estimate remained imprecise.⁷⁸³

Label instructions differ by country

Australia contraindicates armodafinil during pregnancy. The US label says available data are insufficient to estimate an armodafinil-specific pregnancy risk. The pooled registry adds a safety signal that belongs in the treatment discussion.^780,764,782

Contraception

The US label calls for additional or alternative contraception during treatment and for one month afterward. Australian information includes a two-month precaution for steroidal contraception and a separate one-month general statement. Prescribers should reconcile the exact contraceptive method with the local product information.^764,780

The Chinese study

A 2025 study followed 12 healthy Chinese volunteers given oral armodafinil 200 mg daily for seven days. The parent drug accumulated 1.5-fold, and the sulfone metabolite 7.8-fold. Fever occurred in six participants; no serious adverse event was reported. This short study measured pharmacokinetics and safety.⁷⁸⁴

Competitive sport

The 2026 and published 2027 WADA Lists prohibit modafinil and its optical isomers in competition. Armodafinil is the R-isomer. Athletes need to check the applicable therapeutic-use-exemption requirements.^785,786,765

Common questions

Side effects, timing, interactions, sleep loss and the limits of off-label evidence.

01 What is armodafinil used to treat?

The current US label uses armodafinil to improve wakefulness in adults with excessive sleepiness from narcolepsy, obstructive sleep apnea or shift-work disorder. In sleep apnea, it treats residual sleepiness while CPAP or other airway treatment continues.⁷⁶⁴

02 What side effects should I watch for?

Across pooled placebo-controlled sleep-disorder trials with 645 armodafinil and 445 placebo recipients, headache occurred in 17% versus 9%, nausea in 7% versus 3%, dizziness in 5% versus 2%, and insomnia in 5% versus 1%. The label also warns about serious rash, multiorgan hypersensitivity, psychiatric reactions, persistent sleepiness and cardiovascular effects.⁷⁶⁴

03 How quickly does armodafinil work, and how long does it last?

In healthy-subject pharmacokinetic studies, armodafinil reached peak concentration about two hours after a fasting dose and had an apparent terminal half-life near 15 hours. Food changed little overall exposure but delayed the peak by about two to four hours, so the onset and later exposure can shift.^764,766

04 How is armodafinil different from modafinil?

Armodafinil is the isolated R-enantiomer, while modafinil contains both R- and S-enantiomers. A 211-person shift-work trial reported response rates of 72.12% with armodafinil and 74.29% with modafinil; the endpoint was subjective sleepiness, and the study was not an equivalence design.^765,769

05 What do labels and trials say about timing, food and studied doses?

The US label describes once-daily morning use for narcolepsy or sleep-apnea sleepiness and use about one hour before the work shift for shift-work disorder. The tablets can be taken with or without food, but food delayed the concentration peak by about two to four hours; the trials described here studied oral doses of 150 mg or 250 mg in adults with specified sleep disorders.^{764,766,767,768}

06 Is generic armodafinil available, and what affects access or cost?

FDA records include multiple armodafinil applications, including generic approvals. Specific availability and out-of-pocket cost vary by product and coverage.⁷⁸⁷

07 Which armodafinil interactions matter?

Armodafinil can lower exposure to steroidal contraceptives and cyclosporine and raise exposure to some CYP2C19 substrates such as omeprazole, phenytoin and diazepam. The US label advises additional or alternative contraception during treatment and for one month afterward; Australian product information has a separate two-month precaution for steroidal contraceptives and a one-month general contraception statement.^764,780

08 What do comparisons with other stimulants show?

A study of 135 healthy men during acute sleep loss compared armodafinil with lisdexamfetamine and placebo. Both active medicines prolonged time awake and improved sustained attention. The study tested a single exposure during sleep deprivation.⁷⁷⁰

09 Does armodafinil affect appetite or body weight?

Decreased appetite and anorexia each appeared in 1% of armodafinil-treated participants and 0% of placebo participants in the pooled label table. Weight management is not a labeled use.⁷⁶⁴

10 Does armodafinil improve focus or treat ADHD?

Armodafinil can improve sustained attention: 48 Naval air traffic control students had fewer attention lapses with armodafinil than placebo after a standard workday. The abstract leaves their level of rest unclear. ADHD is not a use in the current US label.^789,764

11 What does armodafinil add for sleep apnea patients using CPAP?

Two 12-week US-label trials randomized 395 and 263 adults who remained excessively sleepy despite documented CPAP treatment. Armodafinil improved mean wake latency by about 3.4 to 3.9 minutes and 3.6 minutes over placebo, respectively. CPAP continued throughout both trials.⁷⁶⁴

12 Does daily use lead to tolerance or weaker effects?

A 743-person open-label extension studied longer-term use in people with treated sleep disorders; 420 participants completed at least 12 months, and observed wakefulness and clinical ratings remained improved from month 1 onward. The study had no control group, 95 participants stopped because of adverse events, and the label also records postmarketing tolerance reports without a known frequency.^778,764

13 Is armodafinil addictive, and what happens after stopping?

Armodafinil is a US Schedule IV controlled substance, and the label describes abuse, physical dependence and withdrawal after abrupt stopping or a large dose reduction following chronic use. Reported withdrawal symptoms include shaking, sweating, nausea, confusion, aggression, fatigue, insomnia, depression and headache, without a reliable frequency.^764,779

14 What is known about blood pressure and heart effects?

In short preapproval sleep-disorder trials, mean blood pressure was 1.2 to 4.3 mmHg higher than placebo across study groups, and mean pulse was 0.9 to 3.5 beats per minute higher. New or increased antihypertensive treatment was needed by 2.9% with armodafinil and 1.8% with placebo.⁷⁶⁴

15 How does armodafinil promote wakefulness?

The exact wake-promoting mechanism is not fully known. The label says armodafinil has wake-promoting actions similar to modafinil; modafinil binds the dopamine transporter and reduces dopamine reuptake rather than directly releasing dopamine.⁷⁶⁴